Deramciclane: Egis

Current Opinion in Investigational Drugs

Volumn 3, Issue 2, 2002, Pages 289-294

  Kõks, Sulev ^a   Vasar, Eero ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE; CERULETIDE; CHLORDIAZEPOXIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DERAMCICLANE FUMARATE; DIAZEPAM; DRUG METABOLITE; NORDERAMCICLANE; PAROXETINE; PLACEBO; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST; UNCLASSIFIED DRUG;

ANTICONVULSANT ACTIVITY; ANXIETY NEUROSIS; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BORNANES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUGS, INVESTIGATIONAL; HUMANS; LETHAL DOSE 50; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 0036226591     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Psychopharmacology of a new anxiolytic agent, EGYT-3886
2. Egyt-3886
3. Inhibition of high-affinity synaptosomal uptake of γ-aminobutyric acid by a bicyclo-heptane derivative
4. Synthesis and anxiolytic activity of a new camphor derivative (deramciclane, EGIS-3886)
5. Receptor binding profile and anxiolytic-type activity of deramciclane (EGIS-3886) in animal models
6. Absorption characteristics of deramciclane in vitro, in situ and in vivo
7. Comparative pharmacokinetics of deramciclane in rat, dog, rabbit and man after the administration of a single oral dose of 3 mg/kg
8. Pharmacokinetics of deramciclane in dogs
9. Decrease of gluconeogenesis by deramciclane is counteracted by cytochrome P450 inhibitors
10. 2 receptors
11. mCPP-induced anxiety in the light-dark box in rats - A new method for screening anxiolytic activity
12. Plasma protein binding of deramciclane in different species
13. 2C receptors in affective disorders
14. Announcement on the year 2000 financial statements of the Orion Group
15. Orion Group interim report 1-3/2001
16. Orion Pharma and Pharmacia announce collaboration to develop and commercialize new anxiety medication
17. Positive data for Zanaflex in complications of brain damage
18. The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers
19. 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze
20. Oral, intraperitoneal and intravenous pharmacokinetics of deramciclane and its N-desmethyl metabolite in the rat
21. Deramciclane inhibits N-methyl-D-aspartate receptor function
22. Pharmacokinetics and safety of deramciclane during multiple oral dosing
23. Differential EEG effects of the anxiolytic drugs, deramciclane (EGIS-3886), ritanserin and chlordiazepoxide in rats
24. 3H]D-aspartate release by deramciclane
25. 2C receptor down-regulation
26. Pharmacia Corp business briefing
27. 2A receptor occupancy of deramciclane in humans after a single oral administration - A positron emission tomography study
28. Whole-body autoradiography and quantitative organ-level distribution of deramciclane in rats
29. The single dose pharmacokinetics and safety of deramciclane during multiple oral dosing
30. Deramciclane in the treatment of patients with generalized anxiety disorder: A randomized, double-blind, placebo-controlled, dose-finding study